|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PKIB |
Gene summary for PKIB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PKIB | Gene ID | 5570 |
| Gene name | cAMP-dependent protein kinase inhibitor beta | |
| Gene Alias | PRKACN2 | |
| Cytomap | 6q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | Q9C010 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5570 | PKIB | GSM4909281 | Human | Breast | IDC | 9.32e-07 | -2.56e-01 | 0.21 |
| 5570 | PKIB | GSM4909282 | Human | Breast | IDC | 3.54e-03 | -2.17e-01 | -0.0288 |
| 5570 | PKIB | GSM4909285 | Human | Breast | IDC | 1.05e-04 | -2.50e-01 | 0.21 |
| 5570 | PKIB | GSM4909286 | Human | Breast | IDC | 5.51e-06 | -2.59e-01 | 0.1081 |
| 5570 | PKIB | GSM4909290 | Human | Breast | IDC | 5.58e-11 | 5.36e-01 | 0.2096 |
| 5570 | PKIB | GSM4909291 | Human | Breast | IDC | 1.92e-03 | -2.74e-01 | 0.1753 |
| 5570 | PKIB | GSM4909293 | Human | Breast | IDC | 2.26e-11 | 4.14e-01 | 0.1581 |
| 5570 | PKIB | GSM4909294 | Human | Breast | IDC | 4.05e-06 | 4.13e-01 | 0.2022 |
| 5570 | PKIB | GSM4909296 | Human | Breast | IDC | 1.07e-02 | -1.66e-01 | 0.1524 |
| 5570 | PKIB | GSM4909297 | Human | Breast | IDC | 1.50e-04 | -5.48e-02 | 0.1517 |
| 5570 | PKIB | GSM4909298 | Human | Breast | IDC | 2.64e-08 | -2.71e-01 | 0.1551 |
| 5570 | PKIB | GSM4909301 | Human | Breast | IDC | 9.39e-03 | 3.64e-01 | 0.1577 |
| 5570 | PKIB | GSM4909307 | Human | Breast | IDC | 1.32e-17 | 6.32e-01 | 0.1569 |
| 5570 | PKIB | GSM4909308 | Human | Breast | IDC | 1.80e-72 | 1.09e+00 | 0.158 |
| 5570 | PKIB | GSM4909311 | Human | Breast | IDC | 2.75e-14 | -2.97e-01 | 0.1534 |
| 5570 | PKIB | GSM4909312 | Human | Breast | IDC | 2.37e-11 | -2.66e-01 | 0.1552 |
| 5570 | PKIB | GSM4909319 | Human | Breast | IDC | 8.85e-12 | -2.70e-01 | 0.1563 |
| 5570 | PKIB | GSM4909320 | Human | Breast | IDC | 2.37e-03 | -2.97e-01 | 0.1575 |
| 5570 | PKIB | GSM4909321 | Human | Breast | IDC | 1.02e-05 | 1.69e-01 | 0.1559 |
| 5570 | PKIB | M5 | Human | Breast | IDC | 5.88e-05 | 6.94e-01 | 0.1598 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005134814 | Breast | IDC | negative regulation of transferase activity | 39/1434 | 268/18723 | 7.89e-05 | 1.56e-03 | 39 |
| GO:190435813 | Breast | IDC | positive regulation of telomere maintenance via telomere lengthening | 10/1434 | 37/18723 | 3.45e-04 | 5.07e-03 | 10 |
| GO:001083313 | Breast | IDC | telomere maintenance via telomere lengthening | 16/1434 | 81/18723 | 3.70e-04 | 5.30e-03 | 16 |
| GO:200057313 | Breast | IDC | positive regulation of DNA biosynthetic process | 14/1434 | 66/18723 | 3.96e-04 | 5.54e-03 | 14 |
| GO:200027813 | Breast | IDC | regulation of DNA biosynthetic process | 19/1434 | 106/18723 | 4.05e-04 | 5.60e-03 | 19 |
| GO:190435612 | Breast | IDC | regulation of telomere maintenance via telomere lengthening | 13/1434 | 61/18723 | 6.03e-04 | 7.57e-03 | 13 |
| GO:000700413 | Breast | IDC | telomere maintenance via telomerase | 14/1434 | 69/18723 | 6.37e-04 | 7.94e-03 | 14 |
| GO:00459369 | Breast | IDC | negative regulation of phosphate metabolic process | 53/1434 | 441/18723 | 7.21e-04 | 8.79e-03 | 53 |
| GO:00105639 | Breast | IDC | negative regulation of phosphorus metabolic process | 53/1434 | 442/18723 | 7.60e-04 | 9.25e-03 | 53 |
| GO:003221212 | Breast | IDC | positive regulation of telomere maintenance via telomerase | 9/1434 | 34/18723 | 8.01e-04 | 9.58e-03 | 9 |
| GO:005197312 | Breast | IDC | positive regulation of telomerase activity | 9/1434 | 34/18723 | 8.01e-04 | 9.58e-03 | 9 |
| GO:000072312 | Breast | IDC | telomere maintenance | 21/1434 | 131/18723 | 9.62e-04 | 1.09e-02 | 21 |
| GO:00718976 | Breast | IDC | DNA biosynthetic process | 26/1434 | 180/18723 | 1.28e-03 | 1.35e-02 | 26 |
| GO:200125212 | Breast | IDC | positive regulation of chromosome organization | 15/1434 | 82/18723 | 1.28e-03 | 1.35e-02 | 15 |
| GO:000627812 | Breast | IDC | RNA-dependent DNA biosynthetic process | 14/1434 | 75/18723 | 1.50e-03 | 1.51e-02 | 14 |
| GO:003221012 | Breast | IDC | regulation of telomere maintenance via telomerase | 11/1434 | 53/18723 | 1.95e-03 | 1.86e-02 | 11 |
| GO:00330445 | Breast | IDC | regulation of chromosome organization | 26/1434 | 187/18723 | 2.22e-03 | 2.06e-02 | 26 |
| GO:005197212 | Breast | IDC | regulation of telomerase activity | 10/1434 | 47/18723 | 2.54e-03 | 2.28e-02 | 10 |
| GO:003220412 | Breast | IDC | regulation of telomere maintenance | 14/1434 | 80/18723 | 2.83e-03 | 2.48e-02 | 14 |
| GO:003220612 | Breast | IDC | positive regulation of telomere maintenance | 10/1434 | 52/18723 | 5.49e-03 | 4.03e-02 | 10 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PKIB | SNV | Missense_Mutation | novel | c.31G>T | p.Asp11Tyr | p.D11Y | Q9C010 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.87) | TCGA-OL-A6VO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| PKIB | SNV | Missense_Mutation | c.105N>G | p.Asn35Lys | p.N35K | Q9C010 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PKIB | SNV | Missense_Mutation | rs752581156 | c.98N>A | p.Arg33His | p.R33H | Q9C010 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PKIB | SNV | Missense_Mutation | c.62N>A | p.Gly21Glu | p.G21E | Q9C010 | protein_coding | tolerated(0.08) | possibly_damaging(0.522) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| PKIB | deletion | Frame_Shift_Del | novel | c.64delG | p.Val22SerfsTer40 | p.V22Sfs*40 | Q9C010 | protein_coding | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| PKIB | SNV | Missense_Mutation | novel | c.101N>A | p.Arg34Gln | p.R34Q | Q9C010 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PKIB | SNV | Missense_Mutation | novel | c.210N>C | p.Glu70Asp | p.E70D | Q9C010 | protein_coding | deleterious(0.02) | possibly_damaging(0.755) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PKIB | SNV | Missense_Mutation | novel | c.116N>G | p.Asp39Gly | p.D39G | Q9C010 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PKIB | SNV | Missense_Mutation | c.199N>C | p.Glu67Gln | p.E67Q | Q9C010 | protein_coding | tolerated(0.51) | benign(0.005) | TCGA-33-6737-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | gemcitabine | PD | |
| PKIB | SNV | Missense_Mutation | novel | c.45N>T | p.Met15Ile | p.M15I | Q9C010 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-NC-A5HI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |